Colossal Biosciences, a Dallas, TX-based biosciences and genetic engineering company, raised $60M in Series A financing.
The round, which brought total funding to $75M, was led by Thomas Tull and At One Ventures with participation from Untamed Planet, Animoca Brands, Breyer Capital, Animal Capital, Arch Ventures co-founder Robert Nelsen, Paris Hilton, Bold Capital, First Light Capital Group, Boost VC, Jazz Ventures, Builders VC, Green Sands Equity, Draper Associates, Charles Hoskinson, among others.
The company intends to use the funds to accelerate:
- the development of its genetic tools and technologies including software, wetware, and artificial wombs to advance species preservation and restoration as well as further developing human genetic technologies, and
- hiring across computational biology, embryology, stem cell biology, software engineering, advanced biology, medical device hardware, and genomics.
Founded by technology and software entrepreneur Ben Lamm and geneticist and serial biotech entrepreneur George Church, Ph.D. Colossal creates technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company applies CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth.
Through transparency and collaboration with nonprofits, conservation groups, governments, and the general public, Colossal aims to develop genetic toolkits and support DNA databases to aid in the restoration, diversification and rewilding of endangered species. This work and collaboration will also enable comprehensive population-based sequencing and computational analysis of elephants and mammoth genomes, genome editing, and viral disease resistance, as well as ex-vivo development.
FinSMEs
09/03/2022